



European Federation of Pharmaceutical
Industries and Associations



創薬力向上のための官民協議会に対するEFPIAの見解




2025年6月
一般社団法人 欧州製薬団体連合会
EFPIA Japan 会長 岩屋 孝彦




日本の医薬品研究開発費の成長率は米国・欧州・中国に比べ低い 世界の市場における日本のシェアは減少している

医薬品研究開発費の推移



出典: Economic footprint of the pharmaceutical industry in Europe EFPIA, PWC Nov. 2024

世界の医薬品市場における各国の比率



出所: Copyright © 2025 IQVIA. IQVIA World Review, Data Period 2010から2023
をもとに医薬産業政策研究所にて作成 (無断転載禁止)
出典: 日本製薬工業協会 DATA BOOK 2025

EFPIAは「イノベーションの推進」と「社会保障の持続性」の両立を見据えた 医薬品産業政策の構築に貢献します



* EFPIA Director General, Nathalie Moll

Despite R&D spending growing slowly, the scale and pace of the downward trends in Europe's global share of R&D investment shows that there is only a finite time to turn things around.

Boosting European competitiveness to kickstart growth requires concerted, collective action; urgent implementation of a coherent life sciences strategy for Europe would be a good start to futureproofing the sector."



European Federation of Pharmaceutical
Industries and Associations



EFPIA's views on the public-private council for Innovative Drug Discovery




June 2025
EFPIA Japan Chair
Takahiko Iwaya



Growth rate of pharmaceutical R&D expenditure in Japan is lower than in the US, Europe, and China.
Japan's share of the global market is declining.




PHARMACEUTICAL R&D EXPENDITURE



Source: Economic footprint of the pharmaceutical industry in Europe EFPIA, PWC Nov. 2024

GLOBAL MARKET SHARE



Source: Copyright © 2025 IQVIA. IQVIA Japan, Calculated based on IQVIA World Review, Data Period 2010-2023
 by Office of Pharmaceutical Industry Research (Reprinted with permission)
 Cited from the Japan Pharmaceutical Manufacturers Association DATA BOOK 2025.

EFPIA want to contribute to the development of pharmaceutical industry policies that balance “promoting innovation” and “sustaining social security.”



*** EFPIA Director General, Nathalie Moll**

Despite R&D spending growing slowly, the scale and pace of the downward trends in Europe’s global share of R&D investment shows that there is only a finite time to turn things around.

Boosting European competitiveness to kickstart growth requires concerted, collective action; urgent implementation of a coherent life sciences strategy for Europe would be a good start to futureproofing the sector.”